Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

Among 52 evaluable patients, the group who received a 2 mg/kg dose of the topoisomerase I inhibitor had an objective response rate (ORR) of 34.6%, and the group receiving a dose of 2.4 mg/kg had ...

Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025AVA6103 IND-enabling studies underway with a Phase 1 trial ...

In June 2024, Jiangsu Alphamab entered into a research and collaboration agreement with ArriVent BioPharma, Inc. to use Jiangsu Alphamab's proprietary linker-payload (Alphatecan) and glycan-specific ...

MacroGenics, Inc.’s MGNX share price has dipped by 14.19%, which has investors questioning if this is right time to buy.

We have three antibody drug conjugate molecules, 2 in clinical development, 1 in preclinical studies, that each incorporate a novel glycan-linked topoisomerase inhibitor-based payload, which are ...